Cargando…

Evaluation of rivaroxaban versus warfarin for the treatment of cerebral vein thrombosis: A case-control blinded study

Background: Anticoagulation therapy following cerebral vein thrombosis (CVT) can improve mortality and morbidity. Vitamin K antagonists are currently the routine oral anticoagulant used for CVT; while by introduction of rivaroxaban, a direct factor Xa inhibitor, the attentions have been deviated tow...

Descripción completa

Detalles Bibliográficos
Autores principales: Khorvash, Fariborz, Farajpour-Khanaposhtani, Mohammad Javad, Hemasian, Helia, Saadatnia, Sayed Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984779/
http://dx.doi.org/10.18502/cjn.v20i3.7687
_version_ 1784682254003339264
author Khorvash, Fariborz
Farajpour-Khanaposhtani, Mohammad Javad
Hemasian, Helia
Saadatnia, Sayed Mohammad
author_facet Khorvash, Fariborz
Farajpour-Khanaposhtani, Mohammad Javad
Hemasian, Helia
Saadatnia, Sayed Mohammad
author_sort Khorvash, Fariborz
collection PubMed
description Background: Anticoagulation therapy following cerebral vein thrombosis (CVT) can improve mortality and morbidity. Vitamin K antagonists are currently the routine oral anticoagulant used for CVT; while by introduction of rivaroxaban, a direct factor Xa inhibitor, the attentions have been deviated toward novel agents, but the evidence is not strong. The current study is aimed to compare the efficacy and safety of rivaroxaban versus warfarin for anticoagulation therapy of CVT. Methods: The current randomized clinical trial has been conducted on 50 patients with CVT among which, 25 ones were randomly allocated to rivaroxaban treatment (20 mg per day for three months) and remained 25 ones to warfarin treatment [adjusted based on international normalized ratio (INR) of 2-3]. The Modified Rankin Scale (mRS) and clinical investigations, including the incidence of seizure, papilledema, intra/extra-cranial bleeding, blurred vision, headache, nausea and vomiting, and death were evaluated at discharge time and within 3 and 6 months following CVT incidence; eventually, two groups were compared. Results: Comparison of mRS scores between the groups revealed significant differences in none of the interval assessments, at the time of admission (P = 0.510), within three months (P = 0.630), and within six months (P = 0.990), while both of the approaches led to significant decrease in mRS scores following both of the treatments (P < 0.001). The comparison of drug-related adverse effects showed insignificant difference between warfarin versus rivaroxaban (P > 0.050). Conclusion: Based on this study, rivaroxaban is an efficacious agent for the treatment of CVT without remarkable adverse effects.
format Online
Article
Text
id pubmed-8984779
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Tehran University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-89847792022-04-15 Evaluation of rivaroxaban versus warfarin for the treatment of cerebral vein thrombosis: A case-control blinded study Khorvash, Fariborz Farajpour-Khanaposhtani, Mohammad Javad Hemasian, Helia Saadatnia, Sayed Mohammad Curr J Neurol Original Article Background: Anticoagulation therapy following cerebral vein thrombosis (CVT) can improve mortality and morbidity. Vitamin K antagonists are currently the routine oral anticoagulant used for CVT; while by introduction of rivaroxaban, a direct factor Xa inhibitor, the attentions have been deviated toward novel agents, but the evidence is not strong. The current study is aimed to compare the efficacy and safety of rivaroxaban versus warfarin for anticoagulation therapy of CVT. Methods: The current randomized clinical trial has been conducted on 50 patients with CVT among which, 25 ones were randomly allocated to rivaroxaban treatment (20 mg per day for three months) and remained 25 ones to warfarin treatment [adjusted based on international normalized ratio (INR) of 2-3]. The Modified Rankin Scale (mRS) and clinical investigations, including the incidence of seizure, papilledema, intra/extra-cranial bleeding, blurred vision, headache, nausea and vomiting, and death were evaluated at discharge time and within 3 and 6 months following CVT incidence; eventually, two groups were compared. Results: Comparison of mRS scores between the groups revealed significant differences in none of the interval assessments, at the time of admission (P = 0.510), within three months (P = 0.630), and within six months (P = 0.990), while both of the approaches led to significant decrease in mRS scores following both of the treatments (P < 0.001). The comparison of drug-related adverse effects showed insignificant difference between warfarin versus rivaroxaban (P > 0.050). Conclusion: Based on this study, rivaroxaban is an efficacious agent for the treatment of CVT without remarkable adverse effects. Tehran University of Medical Sciences 2021-07-06 /pmc/articles/PMC8984779/ http://dx.doi.org/10.18502/cjn.v20i3.7687 Text en Copyright © 2021 Iranian Neurological Association, and Tehran University of Medical Sciences. Published by Tehran University of Medical Sciences. https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license (https://creativecommons.org/licenses/by-nc/4.0/). Non-commercial uses of the work are permitted, provided the original work is properly cited.
spellingShingle Original Article
Khorvash, Fariborz
Farajpour-Khanaposhtani, Mohammad Javad
Hemasian, Helia
Saadatnia, Sayed Mohammad
Evaluation of rivaroxaban versus warfarin for the treatment of cerebral vein thrombosis: A case-control blinded study
title Evaluation of rivaroxaban versus warfarin for the treatment of cerebral vein thrombosis: A case-control blinded study
title_full Evaluation of rivaroxaban versus warfarin for the treatment of cerebral vein thrombosis: A case-control blinded study
title_fullStr Evaluation of rivaroxaban versus warfarin for the treatment of cerebral vein thrombosis: A case-control blinded study
title_full_unstemmed Evaluation of rivaroxaban versus warfarin for the treatment of cerebral vein thrombosis: A case-control blinded study
title_short Evaluation of rivaroxaban versus warfarin for the treatment of cerebral vein thrombosis: A case-control blinded study
title_sort evaluation of rivaroxaban versus warfarin for the treatment of cerebral vein thrombosis: a case-control blinded study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984779/
http://dx.doi.org/10.18502/cjn.v20i3.7687
work_keys_str_mv AT khorvashfariborz evaluationofrivaroxabanversuswarfarinforthetreatmentofcerebralveinthrombosisacasecontrolblindedstudy
AT farajpourkhanaposhtanimohammadjavad evaluationofrivaroxabanversuswarfarinforthetreatmentofcerebralveinthrombosisacasecontrolblindedstudy
AT hemasianhelia evaluationofrivaroxabanversuswarfarinforthetreatmentofcerebralveinthrombosisacasecontrolblindedstudy
AT saadatniasayedmohammad evaluationofrivaroxabanversuswarfarinforthetreatmentofcerebralveinthrombosisacasecontrolblindedstudy